Bailard’s Astria Therapeutics ATXS Stock Holding History

Bailard’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-26,500	Closed	-$193K	–	756
2025 Q3	$193K	Hold	26,500	–	–	﹤0.01%	737
2025 Q2	$142K	Buy	+26,500	New	+$128K	﹤0.01%	732

Other funds holding ATXS

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bailard's ATXS Position: Q4 2025 in Review

Bailard sold out of Astria Therapeutics (ATXS) in Q4 2025, closing a stake of 26,500 shares — an estimated $193K sold.

Bailard first reported a position in ATXS in Q2 2025 and held it in 2 quarters. The position peaked at $193K in Q3 2025. 141 funds tracked by Wall St. Rank hold ATXS as of Q4 2025.

Bailard reported no remaining Astria Therapeutics position as of Q4 2025 after selling out during the quarter.
Bailard sold 26,500 Astria Therapeutics shares in Q4 2025, an estimated $193K.
Bailard first reported a position in Astria Therapeutics in Q2 2025 and held it in 2 quarters.
Bailard's Astria Therapeutics position peaked at $193K in Q3 2025.
141 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2025.

Based on Bailard's 13F filing for Q4 2025, filed 4 Feb 2026.